Alembic Pharmaceuticals reports strong Q2 2025 financial growth

Alembic Pharmaceuticals Limited announced consolidated unaudited financial results for the quarter ended September 30, 2025, reporting a total income from operations of ₹1,910.15 Crores, a substantial increase from ₹1,647.98 Crores in the same quarter of the previous year. Net profit after tax attributable to shareholders also rose to ₹184.71 Crores, up from ₹153.41 Crores year-over-year.

For the same period, the company's diluted earnings per share (EPS) improved to ₹9.40, compared to ₹7.79 in the prior year's quarter. Total comprehensive income for the period stood at ₹188.38 Crores. Standalone income from operations reached ₹1,796.24 Crores, with profit after tax at ₹179.36 Crores.

These results, published on November 5, 2025, highlight a robust financial performance, reflecting sustained growth across various segments.